Search This Blog

Saturday, June 6, 2026

Pfizer positive Phase 2b results for monthly GLP-1 berobenatide, supporting ongoing Phase 3

 

Pfizer posts positive Phase 2b results for monthly GLP-1 obesity drug berobenatide, supporting ongoing Phase 3 program

  • Phase 2b data showed robust weight loss and favorable tolerability for berobenatide in patients with obesity.
  • Positive results underpin an extensive Phase 3 development program now underway, including evaluation of once-monthly dosing.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)